Alirocumab as add-on therapy to statins: current evidence and clinical potential.

about

Alirocumab as add-on therapy to statins: current evidence and clinical potential.

Item

http://www.wikidata.org/entity/Q55409167

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Alirocumab as add-on therapy to statins: current evidence and clinical potential.

@en

Alirocumab as add-on therapy to statins: current evidence and clinical potential.

@nl

type

Item

label

Alirocumab as add-on therapy to statins: current evidence and clinical potential.

@en

Alirocumab as add-on therapy to statins: current evidence and clinical potential.

@nl

prefLabel

Alirocumab as add-on therapy to statins: current evidence and clinical potential.

@en

Alirocumab as add-on therapy to statins: current evidence and clinical potential.

@nl

P1476

Alirocumab as add-on therapy to statins: current evidence and clinical potential.

@en

P2093

Robert Berent

http://www.w3.org/2001/XMLSchema#string

P2860

The LDL receptor

PCSK9: a key modulator of cardiovascular health

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.

2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.

P304

191-202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1753944718775352

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Johann Auer

P577

2018-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29792380

http://www.w3.org/2001/XMLSchema#string

P932

6009079

http://www.w3.org/2001/XMLSchema#string